Sustainability & Climate

CardCash's record November reveals a major shift in consumer behavior, where shoppers are using discounted gift cards as a tool to fight inflation.

Xtant Medical's new nanOss Strata bone graft isn't just an update; it's a strategic move to disrupt the orthobiologics market. Here's why it matters.

Polyrizon's novel hydrogel shows it can stick to nasal tissue longer without slowing drug delivery, a key innovation in the fight against opioid overdose.

New Phase 2 data shows Elicio's off-the-shelf therapy ELI-002 7P induces "antigen spreading," creating a personalized anti-tumor response.

Beyond a simple acquisition, ZenaTech is executing a bold strategy to digitize the American West, transforming old-guard industries with a DaaS network.

Cadrenal Therapeutics acquires a novel Phase 2 drug for a deadly clotting disorder, a strategic move targeting an underserved $1 billion market.

Praxis Precision Medicines secures a clear path to market for its rare epilepsy drug, blending genetic science with a savvy regulatory strategy.

Ghost Robotics' new arm gives its Vision 60 the power to act. This leap from seeing to doing has huge implications for industries from defense to healthcare.

Brii Biosciences partners with OpenBench, using an AI platform where they only pay for results. Is this the future of de-risking pharmaceutical R&D?

After a decade of failed trials, a new drug shows promise in treating resistant lung cancer by reawakening the immune system and halting its spread.

As elder isolation becomes a public health emergency in Quebec, one non-profit's strategy of sustained human connection offers a powerful brand lesson.

With AI-guided drills and a new discovery, Nevada King aims to transform its Atlanta mine into a major US gold asset. Will the market take notice?

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

Dreame's 2025 holiday sale isn't just about vacuums; it's a strategic play to conquer the UK market with premium tech at aggressive prices.

With its pivotal trial fully enrolled, IDEAYA Biosciences is on track for a 2026 FDA filing for a new treatment in a rare, deadly eye cancer.

A landmark UK study reveals an AI diagnostic tool that predicts heart attacks with stunning accuracy and offers a £25 million lifeline to strained health budgets.

CEAT Specialty's new OTR tyre isn't just rubber—it's a strategic play for India's trillion-dollar infrastructure push, blending tech and market savvy.

Taiwan is building a comprehensive cycling ecosystem, blending high-tech hospitality with infrastructure to capture a $135B global tourism market.

An upcoming memoir, "Beyond the Bronx," details one man's journey from incarceration to entrepreneurship, offering a blueprint for personal reinvention.

The return of a pharma-finance veteran to MediPharm's board isn't just a personnel change; it's a strategic move to secure its global pharmaceutical ambitions.